title: [New treatment options for metastatic melanoma].
authors.affiliation: Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München.
authors.forename: J K
authors.initials: JK
authors.lastname: Tietze
authors.affiliation: Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München.
authors.forename: C
authors.initials: C
authors.lastname: Berking
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004252:DNA Mutational Analysis; D018450:Disease Progression; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D020558:GTP Phosphohydrolases / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D007167:Immunotherapy; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D000074324:Ipilimumab; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors / Q000235:genetics; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D000074324:Ipilimumab; D008565:Membrane Proteins; D010091:Oximes; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human; C561627:dabrafenib